GlassScriptPhysician profile
Melissa Howie
NPI 1285744268
$12,290.73
in general payments reported to CMS, 2019-2025
37 companies · $3,967 in 2025
The $3,967 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $442 · 2022: $1,486 · 2023: $2,972 · 2024: $3,424 · 2025: $3,967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,362.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,581.86 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,541.03 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,312.68 | 2021-2025 | Dupixent |
| Amgen INC. | $1,249.18 | 2022-2025 | Tezspire, Actimmune, Tavneos |
| Genzyme Corporation | $1,045.27 | 2022-2025 | |
| Pfizer INC. | $670.76 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $598.34 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $410.12 | 2021-2025 | Takhzyro, Cuvitru, Eohilia |
| Pharming Healthcare, INC. | $298.14 | 2021-2025 | Ruconest |
| Blueprint Medicines Corporation | $279.21 | 2023-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.01 | 2021-2024 | Spiriva Respimat, Stiolto Respimat |
| Kaleo, INC. | $213.30 | 2022-2024 | Auvi-Q |
| Optinose US, INC. | $208.51 | 2022-2024 | |
| Csl Behring | $183.09 | 2022-2025 | Haegarda, Andembry |
| Abbvie INC. | $153.82 | 2022-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $150.89 | 2023-2025 | Orladeyo |
| Octapharma USA, INC. | $146.96 | 2023-2025 | Cutaquig |
| Genentech USA, INC. | $111.43 | 2023-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $105.24 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $88.19 | 2023-2025 | Capvaxive, Pneumovax 23, Vaxneuvance |
| Leo Pharma INC. | $82.71 | 2024-2025 | Anzupgo, Adbry |
| Hikma Pharmaceuticals USA | $66.42 | 2024-2025 | Ryaltris |
| Grifols USA, LLC | $61.09 | 2024-2025 | Xembify |
| Greer Laboratories, INC. | $56.23 | 2025 | Oralair |
| Ionis Pharmaceuticals, INC. | $48.12 | 2025 | Dawnzera |
| Lilly USA, LLC | $47.02 | 2025 | Ebglyss |
| Sanofi-Aventis U.S. LLC | $45.95 | 2022 | |
| Cycle Pharmaceuticals INC | $44.95 | 2025 | Sajazir |
| Incyte Corporation | $44.02 | 2023-2024 | Opzelura |
| Phadia US INC. | $36.22 | 2023-2025 | Immunocap |
| Azurity Pharmaceuticals, INC. | $31.68 | 2025 | Alvesco |
| Xeris Pharmaceuticals, INC. | $26.15 | 2021 | |
| Kedrion Biopharma, INC. | $24.22 | 2024 | Albuked, Gammaked, Rhogam Ultra-Filtered Plus |
| Aimmune Therapeutics, INC. | $23.76 | 2023 | |
| Arcutis Biotherapeutics, INC. | $19.56 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $17.55 | 2021 | |
| Galderma Laboratories, L.P. | $17.05 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Howie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.